Last reviewed · How we verify
LVT-001
At a glance
| Generic name | LVT-001 |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LVT-001 CI brief — competitive landscape report
- LVT-001 updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI